New drug pricing consensus letter, sign-ons requested.
D000480:Alkynes; D019380:Anti-HIV Agents / Q000191:economics* / Q000627:therapeutic use; D048588:Benzoxazines; D003521:Cyclopropanes; D015224:Dideoxynucleosides / Q000191:economics* / Q000627:therapeutic use*; D017850:Economics, Pharmaceutical; D015658:HIV Infections / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D010078:Oxazines / Q000191:economics* / Q000627:therapeutic use; D018894:Reverse Transcriptase Inhibitors / Q000191:economics* / Q000627:therapeutic use; D014481:United States; D000099227:Abacavir
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D015224:Dideoxynucleosides; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir; C098320:efavirenz